InSite Vision, Inc.
News & Events

Building Momentum
Stay up to date on the latest developments.

InSite Vision, a SUN PHARMA company is an ophthalmic company primarily focused on developing therapies that treat ocular infection and inflammation, glaucoma, and retinal diseases.

InSIte Vision, Sun Pharma’s wholly-owned subsidiary has received approval from US FDA on April 8th, 2016 for its New Drug Application (NDA) related to BromSite (bromfenac ophthalmic solution) 0.075 per cent for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. BromSite is the first non-steroidal anti-inflammatory drug (NSAID) approved by the US FDA to prevent pain and treat inflammation in the eye for patients undergoing cataract surgery.